FDA staff review raises questions about MannKind diabetes device

WASHINGTON (Reuters) - An initial review of MannKind Corp's experimental inhaled insulin device by U.S. Food and Drug Administration staff raised questions about its safety and effectiveness but was less damning than some investors had expected, sending the company's stock up more than 10 percent in pre-market trading.

via Reuters: Health News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://ift.tt/1jY15Rf